The Scientist

» biotherapeutics

Most Recent

image: CAR-T Therapies Get $1 Billion Boost

CAR-T Therapies Get $1 Billion Boost

By | July 1, 2015

The biotech firm Celgene inks a huge collaboration deal with Juno Therapeutics to develop and commercialize new cancer immunotherapies.

0 Comments

image: Who Owns CRISPR?

Who Owns CRISPR?

By | April 3, 2015

With one US patent awarded and many other applications under consideration for the popular genome-editing technology, companies are adopting multiple strategies to navigate the complex intellectual property landscape.

7 Comments

image: The CAR T-Cell Race

The CAR T-Cell Race

By | April 1, 2015

Tumor-targeting T-cell therapies are generating remarkable remissions in hard-to-beat cancers—and attracting millions of dollars of investment along the way.

2 Comments

image: The Second Coming of RNAi

The Second Coming of RNAi

By | September 1, 2014

Now showing clinical progress against liver diseases, the gene-silencing technique begins to fulfill some of its promises.

1 Comment

image: Virus Found in Sf9 Cell Line

Virus Found in Sf9 Cell Line

By | May 22, 2014

A government lab finds a novel virus present in cell lines used for therapeutic production that were thought to be virus-free.

0 Comments

image: Wrestling with Recurrent Infections

Wrestling with Recurrent Infections

By | May 1, 2011

Clostridium difficile is evolving more robust toxicity, repeatedly attacking its victims, and driving the search for alternative therapies to fight the infection.

6 Comments

Popular Now

  1. What Budget Cuts Might Mean for US Science
    News Analysis What Budget Cuts Might Mean for US Science

    A look at the historical effects of downsized research funding suggests that the Trump administration’s proposed budget could hit early-career scientists the hardest.  

  2. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  3. Opinion: On “The Impact Factor Fallacy”
  4. Unstructured Proteins Help Tardigrades Survive Desiccation
Business Birmingham